Analysts Set Integra LifeSciences Holdings Co. (NASDAQ:IART) Target Price at $18.63

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) has earned a consensus recommendation of "Reduce" from the nine brokerages that are covering the company, MarketBeat reports. Four research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $18.63.

Several equities analysts have weighed in on IART shares. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Truist Financial reduced their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. JPMorgan Chase & Co. decreased their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. JMP Securities cut their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Finally, Wells Fargo & Company decreased their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IART. Romano Brothers AND Company purchased a new position in shares of Integra LifeSciences during the fourth quarter valued at $204,000. Mitsubishi UFJ Asset Management UK Ltd. bought a new position in Integra LifeSciences during the 4th quarter worth about $204,000. Nisa Investment Advisors LLC increased its position in Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after purchasing an additional 2,800 shares during the period. Choreo LLC increased its position in Integra LifeSciences by 29.9% during the 4th quarter. Choreo LLC now owns 22,274 shares of the life sciences company's stock valued at $500,000 after purchasing an additional 5,123 shares during the period. Finally, Empowered Funds LLC bought a new stake in shares of Integra LifeSciences in the 4th quarter valued at about $180,000. Institutional investors own 84.78% of the company's stock.

Integra LifeSciences Price Performance

NASDAQ:IART traded down $0.36 during trading hours on Tuesday, hitting $12.30. 989,046 shares of the stock traded hands, compared to its average volume of 1,043,354. The company has a market cap of $955.86 million, a price-to-earnings ratio of -136.65, a price-to-earnings-growth ratio of 0.73 and a beta of 1.27. Integra LifeSciences has a 1 year low of $11.60 and a 1 year high of $32.66. The stock has a 50 day moving average price of $17.03 and a 200 day moving average price of $21.31. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The firm had revenue of $382.65 million for the quarter, compared to analysts' expectations of $381.17 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm's quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.55 EPS. Sell-side analysts forecast that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.